Technology

Virex Pharma has developed novel formulations for a broad spectrum antiviral drug that has been used since 1977 to treat diseases such as Hepatitis B & C intravenously. The Company has formulated the antiviral drug as a nano-emulsion allowing it to be administered via inhalation and nasal spray for treatment of viral respiratory and encephalitic infections respectively.

GlyXine^© has been specifically formulated as a nanoemulsion.  Nanoemulsions are beneficial in drug delivery as they can help increase the solubility and bioavailability of poorly soluble drugs. They can improve the effectiveness of the drug and potentially reduce the required dose.  Nanoemulsions are also small in size, which allows them to more easily penetrate the body’s tissues, potentially improving the targeting of the drug to specific cells or organs.  Additionally, nanoemulsions are stable, which allows them to maintain their structure and release the drug in a controlled manner over time.